AVIDA The Vidaza® (Azacitidine) Patient Registry (AVIDA)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This registry is a prospective, multi-center, observational study compiling data on the natural history and management of patients receiving Vidaza, and will provide unique insights into the management of myelodysplastic syndromes (MDS) and other hematological disorders and the impact of these disorders on patients.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
Child, Adult, Senior
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Community-based hematology/oncology centers
Patient who is deemed appropriate for treatment with Vidaza® by his or her clinician, but who has not already started receiving Vidaza® treatment.
Patient who is able to read and speak English.
Patient who is willing and able to provide informed consent.
Patient who agrees to complete patient assessment questionnaires.
Patients who are currently being treated with Vidaza®.
Patients who are concurrently participating in a clinical trial.
Patients unwilling or unable to complete the baseline and follow-up questionnaires.
Patients who are deemed inappropriate for treatment with Vidaza®.